• Aurinia Pharmaceuticals raised 2026 revenue guidance to $325 million-$330 million from $315 million-$325 million.
• Net product sales guidance narrowed to $310 million-$315 million from $305 million-$315 million.
• Revenue for the nine months ended September 30 rose 19% to $244.6 million.
• Net income increased 35% to $103.5 million; operating cash flow climbed 46% to $131.5 million.
• A new AURORA 1 analysis linked LUPKYNIS to a 53% reduction in risk of renal-related events or death versus placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.